Polycythaemia vera;Polyzythamia vera

Deutsche Medizinische Wochenschrift

Volumn 125, Issue 41, 2000, Pages 1243-1247

  Lengfelder, E ^a   Hehlmann, R ^a  

^a Medizinische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA; PHOSPHORUS; PIPOBROMAN; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; QUINAZOLINE DERIVATIVE;

HUMAN; LEUKEMIA; MORTALITY; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PROGNOSIS; REVIEW; THROMBOEMBOLISM; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PHLEBOTOMY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOODLETTING; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA; MIDDLE AGED; PHLEBOTOMY; PIPOBROMAN; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 0034644535     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-7728     Document Type: Review

References (41)

1. Polycythemia vera: Stem-cell and probable clonal origin of the disease
2. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
4. Collaborative overview of randomised trials of antiplatelet therapy-III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
5. Diagnosis and classification of the polycythemias
6. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy
7. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols
8. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotent (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells
9. Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia
10. The in vitro and in vivo effect of recombinant interferon α-2a on circulating haematopoietic progenitor cells
11. Complications and causes of death in polycythaemia vera
12. Some speculations on the myeloproliferative syndromes
13. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa
14. From efficacy to safety: A polycythemia vera study group report on hydroxyurea in patients with polycythemia vera
15. Long term treatment of myeloproliferative disease with interferon-α-2b
16. The natural history of 1213 patients followed for 20 years
17. Low dose aspirin in polycythemia vera: A pilot study
18. The present state of pathophysiology and therapeutic trials in polycythemia vera
19. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera
20. Possible selective effect of interferon α-2b on a malignant clone in a case of polycythemia vera
21. Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo
22. Bleeding and thrombosis in myeloproliferative disorders
23. Interferon α in the treatment of polycythemia vera
24. Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone
25. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans
26. Cytogenetic conversion in a case of polycythemia vera treated with interferon-alpha
27. Polycythemia vera in young people; an analysis of 58 cases diagnosed before 40 years
28. The very-long-term course of polycythemia: A complement to the previously published data of the polycythemia vera study group
29. 32p alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age
30. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
31. Leukemic transformation in polycythemia vera: Analysis of risk factors
32. Effect of interferon on pluripotent hematopoietic progenitors (CFU-GEMM) derived from human bone marrow
33. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
34. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera
35. Interferon alfa: Effects of long-term treatment for polycythemia vera
36. Anagrelide: A new drug for treating thrombocytosis
37. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
38. Managemant of polycythemia vera with hydroxyurea
39. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders
40. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: Leukemogenicity with therapeutic implications